Kura Oncology Q3 EPS Estimate Lowered by Leerink Partnrs

Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at Leerink Partnrs cut their Q3 2025 earnings per share estimates for shares of Kura Oncology in a research note issued to investors on Wednesday, May 14th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings of $0.15 per share for the quarter, down from their previous estimate of $0.16. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Leerink Partnrs also issued estimates for Kura Oncology’s Q4 2025 earnings at $0.18 EPS, FY2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.69) EPS.

Other research analysts have also issued research reports about the company. BTIG Research lowered Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. Barclays lowered their price target on Kura Oncology from $32.00 to $11.00 and set an “overweight” rating on the stock in a research report on Friday, May 2nd. Wedbush reissued an “outperform” rating and set a $36.00 target price on shares of Kura Oncology in a report on Tuesday, April 8th. UBS Group decreased their target price on Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Finally, StockNews.com lowered Kura Oncology from a “buy” rating to a “hold” rating in a report on Friday, May 2nd. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Kura Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $24.50.

Kura Oncology Stock Up 3.7%

NASDAQ:KURA opened at $6.24 on Monday. The firm has a market capitalization of $540.23 million, a price-to-earnings ratio of -2.64 and a beta of 0.50. Kura Oncology has a twelve month low of $5.41 and a twelve month high of $23.48. The stock’s 50 day moving average price is $6.39 and its two-hundred day moving average price is $8.65. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The business had revenue of $14.11 million during the quarter, compared to analysts’ expectations of $39.08 million.

Institutional Trading of Kura Oncology

Several large investors have recently modified their holdings of KURA. Barclays PLC grew its holdings in shares of Kura Oncology by 104.5% during the 3rd quarter. Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after purchasing an additional 84,563 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Kura Oncology during the 4th quarter worth $436,000. Moody Aldrich Partners LLC grew its holdings in shares of Kura Oncology by 42.3% during the 4th quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock worth $1,251,000 after purchasing an additional 42,712 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Kura Oncology by 11.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock worth $144,000 after purchasing an additional 1,750 shares in the last quarter. Finally, Jennison Associates LLC acquired a new stake in shares of Kura Oncology during the 4th quarter worth $623,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.